Q4 2018 13F Holders as of 12/31/2018
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
112M
-
Number of holders
-
161
-
Total 13F shares, excl. options
-
57.3M
-
Shares change
-
+2.77M
-
Total reported value, excl. options
-
$1.92B
-
Value change
-
+$53.7M
-
Put/Call ratio
-
0.16
-
Number of buys
-
81
-
Number of sells
-
-97
-
Price
-
$33.48
Significant Holders of NovoCure Ltd - Common Stock (NVCR) as of Q4 2018
214 filings reported holding NVCR - NovoCure Ltd - Common Stock as of Q4 2018.
NovoCure Ltd - Common Stock (NVCR) has 161 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 57.3M shares
of 112M outstanding shares and own 51.17% of the company stock.
Largest 10 shareholders include FMR LLC (11.2M shares), Vanguard Group Inc (6.42M shares), BlackRock Inc. (4.8M shares), BAILLIE GIFFORD & CO (4.5M shares), Capital World Investors (2.79M shares), Darsana Capital Partners LP (2.15M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.93M shares), CREDIT SUISSE AG/ (1.49M shares), STATE STREET CORP (1.29M shares), and TimesSquare Capital Management, LLC (1.28M shares).
This table shows the top 161 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.